Patient safety is our top priority at Novo Nordisk
Sites offering GLP-1 medicines without a prescription, or guaranteeing approval before any evaluation, are operating outside the law
Thats a massive difference
Heres where things get really serious: Chronic, high-dose use of any IGF-1 analog carries theoretical risk of organ growth (visceral tissue, heart, intestines) and potential contribution to tumor growth in individuals with existing but undiagnosed cancers
That convergence of independent findings across diverse research groups adds weight to the overall body of evidence in a way that designed peptides with narrower mechanistic rationales cannot replicate
One day after winning approval of colorectal cancer drug Fruzaqla, the Japanese pharma announced the FDA approval of Adzynma for congenital thrombotic thrombocytopenic purpura (cTTP)